Merck looks for leg up on Bristol with Keytruda’s latest colorectal cancer win
Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won. The immuno-oncology star trumped various chemo regimens at keeping cancer from progressing in previously untreated patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that had either spread to other parts of the body or couldn’t be surgically removed,… Read More »
